logo-loader
viewCircassia Group PLC

Circassia Pharmaceuticals plots a path to profitability through diagnostics

Snapshot

  • Specialty group focused on respiratory diagnostics
  • Growing revenue base; set its sights on profitability
  • Core product assesses the severity of asthma
Circassia Pharmaceuticals PLC -

Quick facts: Circassia Group PLC

Price: 25 GBX

LSE:CIR
Market: LSE
Market Cap: £93.92 m
Follow

 

 

What it does

Circassia Pharmaceuticals PLC (LON:CIR) is a specialty pharma company focused on treating patients with respiratory diseases.

It currently markets two products: NIOX, which is used to help manage asthma

It has several other asthma and COPD treatments in its pipeline, as well as AirNOvent – a portable system that uses electricity to make nitric oxide, which is used to dilate blood vessels in the lungs.

How it's doing

In April, Circassia handed the US rights to two respiratory drugs back to AstraZeneca PLC (LON:AZN) and said it would focus on diagnostics. 

Astra will waive loans and interest of US$149.mln when it takes back the two drugs - Tudorza and Duaklir - though it will retain the 18.9% stake in AIM-listed Circassia that was part of the original deal. 

In a statement, Circassia said it had carried out a strategic review of the business and the options for the two drugs and concluded it was ‘highly unlikely’ it would be able to refinance the loan from Astra.

Ian Johnson, Circassia's executive chairman said the primary focus going forward will be on the group's Niox respiratory diagnostic platform.

NiOX is a tool that measures if a person suffers from asthma and, if they do, the severity of the condition.

By analysing the fractional exhaled nitric oxide (FeNo) present when people breathe out, it can give a readout in less a minute.

What the boss says: Ian Jonhson, chairman

"Upon completion, this transaction will transform Circassia into a debt-free business with a strong revenue-generating business, with which we have the potential to expand into new territories : 

Inflexion points

  • Completion of reversion of Tudorza and Duaklir back to Astra
  • NIOX identifies the severity of asthma in sufferers
  • Breathing problems are central in treating coronavirus

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Circassia Group PLC named herein, including the promotion by the Company of Circassia Group PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Circassia Pharmaceuticals' commercial development...

Circassia Pharmaceuticals PLC's (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott they saw strong growth in the first half of the year alongside a reduction in costs and cash outflows. Revenues for the six months ended June 30 were up 40% year-on-year at £27.9mln, with the...

on 26/9/19

2 min read